$NORD Cashflow Statement | Understand Stock

$NORD

$4.00 +$0.00 (0.0%) Close

$NORD Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2026 12 months to Mar 31, 2026	FY2025 12 months to Mar 31, 2025	FY2024 12 months to Mar 31, 2024	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation – related party
Common Stock issued for services
Stock-based compensation

Shares issued for services
Stock-based compensation
Change in fair value of warrant liability (related party)
Loss on sale of assets
Change in fair value of investment
Non-cash expense of IPR&D
Amortization of website costs
Changes in assets and liabilities:
Prepaid expenses
Prepaid expenses and other current assets
Receivables
Other assets
Accounts payable and accrued expenses
Deferred revenue
Related party payable
Foreign currency remeasurement

Net cash used in operating activities
Cash paid for website costs
Proceeds from sale of plant, property, and equipment
Purchase of plant, property, and equipment
Cash paid for website costs
Cash acquired in business combinations
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Cash distribution to stockholder
Cash paid for stock issuance costs in business combinations
Repurchase of common stock
Gross proceeds
Proceeds from issuance of note payable
Repayment of note payable
Cash advance - related party
Proceeds from Orocidin issuance of common stock in capital raise
Proceeds from exercise of warrants
Net cash provided by financing activities

Net change in cash
Effect of exchange rate on cash
Cash at beginning of period
Cash at end of period
Supplemental disclosures of non-cash information:
Deemed dividend
NoviThera equity issued for intellectual property
Common Stock issued for the acquisition of Bio-Convert
Common Stock issued for the acquisition of Orocidin
Cancellation of liability-classified warrants – related party
Forgiveness of debt - related party

Comments